ESR1 and breast carcinoma: As HRT is one of the most frequently administered pharmaceuticals world-wide, delineating the mechanisms of an altered interaction between PR and ER in cancer is crucial to unravelling the mechanisms that underlie the role of HRT progestins in breast cancer, and would lead to potential strategies for continued development and administration of hormone formulations.